Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Amortizatization of Intangibles (2024 - 2025)

Prelude Therapeutics' Amortizatization of Intangibles history spans 2 years, with the latest figure at $188000.0 for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 108.97% year-over-year to $188000.0; the TTM value through Dec 2025 reached $371000.0, down 76.68%, while the annual FY2025 figure was $371000.0, 76.68% down from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $188000.0 at Prelude Therapeutics, up from $49000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $2.9 million in Q3 2024 and bottomed at -$2.1 million in Q4 2024.